Summary

Molecular biology and gene expression regulation examine the molecular organization, function, and interactions of DNA, RNA, and proteins. This collection covers the mechanisms through which genetic information is replicated, transcribed, processed, translated, and regulated, including transcriptional control, RNA metabolism, post-transcriptional regulation, protein synthesis, and molecular signaling.

Expand All
Entries
Topic Review
Oxidative Stress Responses
Oxidative stress responses are regulated molecular and cellular programs activated when oxidant generation or diminished antioxidant capacity perturbs redox homeostasis beyond physiological redox signaling [1]. They are not synonymous with oxidative stress itself or with antioxidant defenses alone; rather, they comprise sensing of reactive oxygen, nitrogen, or electrophilic species, signal transduction through redox-sensitive protein targets, and effector processes that limit macromolecular damage and re-establish a viable redox state [1][2]. A principal transcriptional arm is the Keap1–Nrf2–antioxidant response element pathway, which induces genes for glutathione and thioredoxin metabolism, xenobiotic detoxification, NADPH regeneration, and antioxidant enzymes [3][4]. Depending on intensity and duration, these responses support adaptive homeostasis, repair, growth arrest, senescence, or regulated cell death [1][2].
  • 4
  • 20 Nov 2026
Topic Review
Next-Generation Sequencing
Next-generation sequencing (NGS) is a collective term in genomics and molecular biology for post-Sanger DNA sequencing platforms that determine nucleotide order at very high throughput by performing many sequencing reactions in parallel on clonally amplified templates or, in some implementations, individual molecules [1]. Rather than denoting a single chemistry, NGS encompasses platform-specific cycles of template preparation, nucleotide incorporation or ligation, signal detection, imaging or electrical measurement, and computational base calling that convert short or long sequence reads into digital genomic data [1][2]. Its defining distinction from capillary Sanger sequencing is scale: millions to billions of reads can be produced in one run, enabling genome-wide assays but requiring bioinformatic alignment, assembly, error modeling, and quality control [2][3].
  • 3
  • 20 Nov 2026
Topic Review
RNA-Seq
RNA-Seq, or RNA sequencing, is a high-throughput transcriptomic method in molecular biology that determines the identity and relative abundance of RNA molecules by converting RNA populations, typically after selection or depletion steps, into sequencing libraries and computationally mapping or assembling the resulting reads [1][2]. Its defining unit of measurement is read count or coverage across transcripts and genomic loci, which supports digital estimation of gene expression and detection of transcript boundaries, splice junctions, sequence variants, and previously unannotated RNAs [1][3]. RNA-Seq differs from hybridization-based expression microarrays because it does not require prior probe design and can interrogate transcripts over a broader dynamic range [1][2]. Single-cell and spatial transcriptomic methods are specialized implementations that add cell or location indexing to RNA-Seq rather than separate molecular principles [4].
  • 3
  • 20 Nov 2026
Topic Review
RT-qPCR
RT-qPCR (reverse transcription quantitative polymerase chain reaction) is a molecular biology technique that quantifies RNA by first converting target RNA into complementary DNA with reverse transcriptase and then measuring PCR product accumulation in real time through fluorescence during exponential amplification [1][2][3]. Its quantitative output is commonly expressed as a quantification-cycle or threshold-cycle value, interpreted using calibration curves for absolute quantification or normalized reference genes and comparative Cq methods for relative expression analysis [1][4]. The term specifically denotes quantification of RNA-derived templates; qPCR alone may quantify DNA without reverse transcription, whereas conventional RT-PCR usually detects amplified cDNA after endpoint PCR and is not intrinsically quantitative [1][2]. Reliable RT-qPCR requires validated assays, controlled RNA quality, reverse-transcription efficiency, amplification efficiency, and transparent reporting to minimize technical bias [1][2].
  • 3
  • 20 Nov 2026
Topic Review
Peptide Stability
Peptide stability is the ability of a peptide to retain its chemical integrity and relevant physical state under specified storage, formulation, or biological conditions [1][2]. Chemical changes can alter individual residues or cleave the backbone, whereas physical instability includes self-association into soluble aggregates, precipitates, or ordered fibrils. Sequence, concentration, pH, temperature, agitation, and contact with surfaces can influence these processes; stability therefore refers to a stated environment and observation period [2]. In biological fluids, resistance to proteolytic degradation contributes to persistence, but circulating exposure also reflects distribution and elimination [1][3]. Stability engineering may involve sequence modification, conformational restriction, formulation changes, or attachment of groups that promote albumin binding [1][4]. These interventions can change biological activity as well as degradation rates. An albumin-binding modification of a PCSK9 inhibitory peptide, for example, improved serum stability and activity in animals despite reducing measured binding potency. Assessment consequently distinguishes molecular integrity and aggregation from retained target binding and functional activity [1][2].
  • 7
  • 15 Nov 2026
Topic Review
Peptide Aptamer
A peptide aptamer is a selected peptide ligand that binds a specific protein, typically through a variable amino acid sequence constrained within a stable protein scaffold [1][2]. In the original system, twenty-residue sequences were inserted into the exposed active-site loop of Escherichia coli thioredoxin, and a yeast two-hybrid screen identified variants recognizing cyclin-dependent kinase 2 [1]. The scaffold restricts the conformations available to the displayed sequence while supporting its intracellular expression. Selection links a binding phenotype to the DNA encoding the ligand, allowing individual aptamers to be recovered and characterized [1][2]. Binding can interfere with a target's catalytic activity or molecular interactions, providing a means to perturb protein function without eliminating the protein itself [3][4]. Specificity tests distinguish recognition of the intended target from binding to related proteins or assay components [2]. Biologically active aptamers can support target validation and identify interaction surfaces for subsequent small-molecule screening, including assays in which compounds displace the bound aptamer [4].
  • 4
  • 15 Nov 2026
Topic Review
Tyrosine Kinase Inhibitor
A tyrosine kinase inhibitor is a compound that suppresses the transfer of phosphate from ATP to tyrosine residues in protein substrates by a tyrosine kinase [1]. Targets include membrane-associated receptor kinases and intracellular nonreceptor kinases involved in cellular signaling. Many inhibitors occupy the ATP-binding region, whereas others bind an allosteric site and stabilize a kinase conformation with reduced catalytic activity [1][2]. Binding can be reversible or involve covalent modification of an appropriately positioned amino acid residue [2]. Individual compounds differ in their recognition of kinase conformations and neighboring binding pockets, producing different selectivity profiles across related enzymes [1][2]. Gefitinib inhibits the epidermal growth factor receptor kinase, with particular receptor mutations associated with increased cellular sensitivity [3]. Conversely, changes in the inhibitor-binding region or amplification of the kinase gene can restore signaling despite drug exposure, as demonstrated for BCR–ABL and imatinib [4]. Reduced tyrosine phosphorylation therefore reflects both inhibitor–kinase binding and the molecular state of the targeted signaling system [1][4].
  • 6
  • 16 Nov 2026
Topic Review
Serine Protease Inhibitors
Serine protease inhibitors are molecules that reduce peptide-bond hydrolysis by proteases whose catalytic mechanism uses a serine residue as the nucleophile [1][2]. They include small organic compounds and inhibitory proteins with distinct binding mechanisms [1][3]. Electrophilic inhibitors can react with the catalytic serine to form covalent complexes, whereas noncovalent inhibitors obstruct substrate recognition or access to the catalytic machinery [1][2]. Serpins inhibit through a coupled cleavage and conformational rearrangement: the protease attacks an exposed reactive loop, which subsequently inserts into the inhibitor's central beta sheet. This movement displaces and distorts the tethered protease, trapping the enzyme in an inactive complex [3]. Other protein inhibitors achieve inhibition through tight binding without this extensive structural transition; tick anticoagulant peptide selectively inhibits coagulation factor Xa [4]. Recognition of residues surrounding the scissile bond and contacts outside the catalytic center contribute to selectivity, so inhibition of one serine protease does not imply equivalent inhibition of the entire enzyme family [1][4].
  • 9
  • 15 Nov 2026
Topic Review
Reuptake Inhibitors
Reuptake inhibitors are compounds that reduce the transporter-mediated return of released neurotransmitters from extracellular spaces into neurons or glial cells [1][2]. By slowing this clearance route, they can increase neurotransmitter availability near receptors and prolong extracellular signaling. Major targets include the serotonin, norepinephrine, and dopamine transporters, which use transmembrane ion gradients to drive neurotransmitter uptake. Individual inhibitors differ in their relative activity at these transporters, producing selective or combined inhibition profiles [1]. Structural studies show that several serotonin reuptake inhibitors occupy the central substrate-binding site and stabilize an outward-open transporter conformation, preventing normal serotonin binding and transport [3][4]. The broader category also includes inhibitors of non-monoamine transporters: glycine transporter 1 can be inhibited by compounds that stabilize an inward-open state [2]. Reuptake inhibition therefore describes interference with a transport process rather than a single binding geometry. Its immediate action is distinct from neurotransmitter synthesis inhibition, transmitter degradation blockade, or direct activation of a neurotransmitter receptor [1][2].
  • 5
  • 15 Nov 2026
Topic Review
Proton Pump Inhibitor
A proton pump inhibitor is an acid-suppressing drug that inhibits the gastric hydrogen–potassium ATPase in the secretory membrane of stomach parietal cells [1]. This ATP-driven pump exchanges intracellular protons for luminal potassium and performs the terminal step in gastric acid secretion [1][2]. Conventional proton pump inhibitors, including omeprazole and related substituted benzimidazoles, are administered as prodrugs [3][4]. Their weakly basic structures favor accumulation in the acidic secretory canaliculi, where protonation promotes conversion into reactive species. These activated compounds form covalent bonds with accessible cysteine residues of the pump, suppressing its proton-transport activity. Acid inhibition can therefore persist after the circulating parent compound has been cleared, with recovery involving restoration of functional pumps [1][3]. The pharmacological class is distinct from potassium-competitive acid blockers, which inhibit the same transporter through a different binding mechanism [2]. Its characteristic combination of acid-associated activation and covalent pump modification connects the chemical properties of the prodrug to prolonged suppression of gastric acid secretion [3][4].
  • 6
  • 15 Nov 2026
  • Page
  • of
  • 8
>>